Cryotherapy Dan Intensitas Nyeri Pada Injeksi Intrakutan

CRYOTHERAPY DAN INTENSITAS NYERI PADA INJEKSI INTRAKUTAN Abstrak Cryotherapy merupakan aplikasi terapi suhu rendah atau dingin yang digunakan untuk berbagai keperluan seperti mengurangi pembengkakan pada trauma, peradangan dan mengurangi nyeri. Cryotherapy juga telah digunakan untuk menangani nyeri pada prosedur penyuntikan seperti penyuntikan subkutan dan intravena. Secara khusus penelitian ini bertujuan untuk mengevaluasi perbedaan efek dari cryotherapy kering dan basah pada intensitas nyeri injeksi intrakutan. Metode: yang digunakan dalam penelitian ini adalah quasi ekperimen dengan post-test design. Pemilihan sample menggunakan teknik purposive sampling untuk memperoleh total 54 responden yang dibagi kedalam dua kelompok. Penelitian ini membandingkan intensitas nyeri kedua kelompok menggunakan numerical pain rating scale. Masing-masing kelompok mendapatkan aplikasi cryotherapy pada area penyuntikan selama 5 menit sebelum dilakukan injeksi intrakutan. Kelompok I diberikan aplikasi cryotherapy dalam bentuk es batu dalam plastik es yang dibungkus kantong kain. Kelompok II diberikan aplikasi washlap yang telah dicelupkan dalam air es. Hasil penelitian menunjukkan bahwa rata-rata intensitas nyeri pada kelompok I berada pada kategori nyeri sedang, dan kelompok II berada pada kategori nyeri berat terkontrol. Uji t-independen menunjukkan bahwa terdapat perbedaan signifikan pada intensitas nyeri diantara kedua kelompok (p<0.05). Dengan demikian aplikasi cryotherapy dengan es batu selama 5 menit lebih efektif mengurangi intensitas nyeri pada injeksi intrakutan. Aplikasi cryotherapy dapat dilakukan untuk mengurangi nyeri pada injeksi intrakutan. CRYOTHERAPY AND PAIN INTENSITY ON INTRACUTANEOUS INJECTION Abstract Cryotherapy is an application of low or cold temperature therapy that is used for various purposes such as reducing swelling in trauma, inflammation and reducing pain. Cryotherapy has also been used to treat pain in injection procedures such as subcutaneous and intravenous injections. In particular, this study aimed to evaluate the differences in the effects of dry and wet cryotherapy on the pain intensity of intracutaneous injection. The method used in this study is quasi experiment with post-test design. The sample selection uses a purposive sampling technique to obtain a total of 54 respondents divided into two groups. This study compared the intensity of pain between the two groups using the numerical pain rating scale. Each group received an application of cryotherapy in the injection area for 5 minutes before intracutaneous injection. Group I was given the application of cryotherapy in the form of ice cubes in ice plastic wrapped in a cloth bag. Group II was given the washlap application which had been dipped in ice water. The results showed that the average pain intensity in group I was in the moderate pain category, and group II was in the category of heavily controlled pain. Independent t-test showed that there were significant differences in pain intensity between the two groups (p <0.05). Thus the application of cryotherapy with ice cube for 5 minutes is more effective in reducing pain intensity in intracutaneous injection. The application of cryotherapy can be done to reduce pain in intracutaneous injection.

Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96

Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/gp96 group than those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/106 cells vs 46.40±10.32 IFN-gama spots/106 cells, 12.14±7.33 IFN-gama spots/106 cells, P<0.01; 164.52±11.22 µg/mL vs 56.32±8.23 µg/mL, 7.56±3.47 µg/mL, P< 0.01). The tumor volume in mAFP/gp96 group was significantly smaller than that in mAFP and gp96 groups (32.46±6.35 mm3 vs 384.16±11.43 mm3, 832.54±12.72 mm3, P< 0.01). Conclusions: The study further confirmed the function of glycoprotein 96s immune adjuvant. Sequential immunization with recombinant mAFP/gp96 vaccine could generate effective antitumor immunity on AFP-producing tumor. The recombined mAFP/gp96 vaccine may be suitable for serving as an immunotherapy for hepatocellular carcinoma.

Anti-Tumor Immunotherapy Elicited by Cross-Link Peptide Vaccine Alpha-Fetoprotein and Heat Shock Protein 70 Complex

Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-heat shock protein (HSP70) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to heat shock protein 70. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/HSP70, whereas single mAFP or HSP70 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenges were carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/HSP70 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/HSP70 group than those in mAFP and HSP70 groups (108.50±11.70 IFN-gama spots/106 cells vs 41.60±10.40 IFN-gama spots/106 cells, 7.32±3.14 IFN-gama spots/106 cells, P<0.01; 156.32±10.42 µg/mL vs 66.52±7.35 µg/mL, 5.73±2.89 µg/mL, P<0.01). The tumor volume in mAFP/HSP70 group was significantly smaller than that in mAFP and HSP70 groups (42.44±7.14 mm3 vs 392.23±12.46 mm3, 838.63±13.84 mm3, P<0.01). Conclusions: The study further confirmed the function of heat shock protein 70’s immune adjuvant. Sequential immunization with recombinant mAFP/HSP70 vaccine could generate effective antitumor immunity on AFP-producing tumor. The recombined mAFP/HSP70 vaccine may be suitable for serving as an immunotherapy for hepatocellular carcinoma.

Methods of acute biological assays in guinea-pigs for the study of toxicity and innocuity of drugs and chemicals

In this study, 602 samples were tested by the following assays performed at the animal facilities (Cedeme) of the Federal University of São Paulo (UNIFESP): 385 for dermal irritability, 90 for ocular irritability (discontinued in 1995), 31 for systemic toxicity by injection, 26 for oral acute toxicity, 15 for toxicity by intracutaneous injection, 15 for skin sensitization, 15 for toxicity of serum and vaccines for human use, 14 for toxicity by intramuscular implantation, 7 for pyrogens, 2 for acute dermal toxicity, and 2 for irritation of mucous membrane. The following agents were tested: cosmetics and related substances (42.0%), chemicals used in industry (32.9%), plastics, rubber, and other polymers (15.9%), agrotoxics (4.0%), medicines (2.7%), and vaccines (2.5%). In the present description, emphasis was given to tests of dermal irritability and sensitization. This work was conducted entirely in animal facilities, according to our general belief that animal facilities at universities, while considering ethic principles and sanitary, genetic, nutritional, and pathophysiological controls, also require laboratories specialized in areas such as transgenics, cryopreservation, ambiental physiology, functional genomics, alternative models, and mainly activities and research on methods in toxicology, as focused in this study.